

Elipovimab

Chemical Properties

CAS No. : 2101210-43-7

Formula:

Molecular Weight:

Storage: Store at low temperature
Store at -20°C

Actual storage temperature shall be subject to the COA.

Biological Description

| | |
|---------------|--|
| Description | Elipovimab is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists. |
| Targets(IC50) | HIV Protease |
| In vitro | In ex vivo assays using PBMCs from HIV-infected individuals, Elipovimab (GS-9722) demonstrates potent ADCC activity against cells expressing viral envelopes. Pre-treatment of NK cells with TLR7 or TLR9 agonists significantly increases Elipovimab-mediated killing of autologous HIV-infected CD4+ T cells and promotes more efficient target cell clearance [1]. |

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481